key: cord-0951477-g8zqumpk authors: van Gils, Marit J.; van Willigen, Hugo D.G.; Wynberg, Elke; Han, Alvin X.; van der Straten, Karlijn; Burger, Judith A.; Poniman, Meliawati; Oomen, Melissa; Tejjani, Khadija; Bouhuijs, Joey H.; Verveen, Anouk; Lebbink, Romy; Dijkstra, Maartje; Appelman, Brent; Lavell, A. H. Ayesha; Caniels, Tom G.; Bontjer, Ilja; van Vught, Lonneke A.; Vlaar, Alexander P.J.; Sikkens, Jonne J.; Bomers, Marije K.; Russell, Colin A.; Kootstra, Neeltje A.; Sanders, Rogier W.; Prins, Maria; de Bree, Godelieve J.; de Jong, Menno D. title: A Single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern date: 2021-12-14 journal: Cell Rep Med DOI: 10.1016/j.xcrm.2021.100486 sha: a4e4f6d08212f7df7c15a97a6ed181e672b27367 doc_id: 951477 cord_uid: g8zqumpk The urgent need for, but limited availability of, SARS-CoV-2 vaccines worldwide has led to widespread consideration of dose sparing strategies. Here, we evaluate the SARS-CoV-2 specific antibody responses following BNT162b2 vaccination in 150 previously SARS-CoV-2-infected individuals from a population-based cohort. One week after first vaccine dose, spike protein antibody levels are 27-fold higher and neutralizing antibody titers 12-fold higher, exceeding titers of fully vaccinated SARS-CoV-2-naive controls, with minimal additional boosting after the second dose. Neutralizing antibody titers against four variants of concern increase after vaccination, however overall neutralization breadth does not improve. Pre-vaccination neutralizing antibody titers and time since infection have the largest positive effect on titers following vaccination. COVID-19 severity and the presence of comorbidities have no discernible impact on vaccine response. In conclusion, a single dose of BNT162b2 vaccine up to 15 months after SARS-CoV-2 infection offers higher neutralizing antibody titers than two vaccine doses in SARS-CoV-2-naive individuals. The unprecedented rapid development and emergency use authorization of several vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) allows for optimism in the global fight against the coronavirus disease 2019 (COVID-19) pandemic 1 . However, in many regions, vaccination campaigns are hampered by limited supply or resources, hence vaccine sparing strategies are desirable. Making use of immunological memory after prior natural SARS-CoV-2 infection 2-4 , single dosing represents one such strategy for vaccines requiring two doses for optimal efficacy. Indeed, a number of recent small studies in health care workers (HCW) have shown similar or higher antibody responses and higher vaccine efficacy to a single dose SARS-CoV-2 mRNA vaccine after prior infection, compared to two doses in SARS-CoV-2-naive individuals [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . However, these studies were A total of 150 participants of the RECoVERED cohort received one or two doses of the BNT162b2 mRNA vaccine after a median of nine months following SARS-CoV-2 infection (interquartile range (IQR) 5-12 months; Figure S1 ). The median age of participants was 51 years (IQR 33-62), 35% were female, 44% had one or more comorbidities and their SARS-CoV-2 infections were classified as mild, moderate, or severe/critical COVID-19 in 33%, 45% and 22% of participants, respectively (Table 1) . Overall, the vaccine was well tolerated with only mild and self-limiting adverse events (Table S1 ). A total of 128 of the 150 participants (84%) reported one or more side effects within 48 hours after the first vaccine dose, with pain at the injection-site (84%) and fatigue (48%) reported most frequently. Similarly, 84 of the 101 participants (83%) who received the second dose of vaccine reported side effects within 48 hours, with pain at injection site (56%) and fatigue (57%) as the most common complaints. The control group consisted of 49 healthy HCW (62% female, median age 44 years (IQR 33-53)) without evidence of previous SARS-CoV-2 infection who received two doses of the BNT162b2 mRNA vaccine. J o u r n a l P r e -p r o o f Following SARS-CoV-2 infection, levels of IgG antibodies binding to S, RBD and N proteins exhibited a wide range, with overall higher levels observed in participants with previous severe/critical COVID-19 ( Figure 1A , S2A). Using a constant decay model which best fit the data, IgG levels declined over time with estimated half-lives of 170 (95% credible interval (CrI): 137 to 228), 148 (95% CrI: 124, 180) and 99 days (95% CrI: 86, 118) for S, RBD and N proteins respectively, independent of peak IgG level or disease severity. Sharp increases in anti-S and anti-RBD IgG were observed 1 week after the first vaccination (median fold increase 22.0 (IQR 7.7-53.1) and 22.55 (IQR 6.5-67.1), respectively) ( Figure 1B, S2B) . No further increases were observed 4 weeks after the first dose (prior to administration of the second dose) and 1 and 4 weeks after the second dose (week 5 and 8; Table S2 ). Using a Bayesian ANOVA model, we found substantial differences in anti-S (95% CrI of difference in effects: 1.22, 1.49) and anti-RBD (95% CrI: 1.23, 1.48) IgG levels between specimens collected before and after the 1st dose of vaccine. All subsequent changes after week 1 were found to be trivial ( Figure S2B ; Table S2 ). Achieved levels after week 1 were similar or higher to those observed four weeks after two vaccinations in the SARS-CoV-2naive HCW control group ( Figure 1B) . When looking at anti-S IgG to four variants of concern (VOCs; Alpha (B1.1.7), Beta (B.1.351), Gamma (P.1) and Delta ( B.1.617.2)), levels were comparable to wild-type Wuhan-Hu-1 (WT) S protein both pre-and post-vaccination, with discernible increases for all VOCs S proteins after vaccination (Figures 1C; Table S2 ). Over time after infection, SARS-CoV-2 neutralizing antibody responses developed with higher titers observed for individuals with more severe COVID-19 disease outcomes ( Figure 2A ). A mixed-effect two-phase decay provided a better fit to the observed waning neutralization titers based on the Watanabe-Akaike information criterion (Table S3) . Decay was faster during the first phase with a median half-life of 74 days (95% CrI: 37, 160) before transitioning into the second phase with a slower decay at median half-life of 153 days (95% CrI: 94, 809), independent of COVID-19 severity and peak neutralizing response. The median transition time point between the two phases was estimated to be on day 123 after onset of symptoms (95% CrI: 50, 183). Prior to vaccination, 132 of 150 (88%) participants still had detectable neutralization titers (ID50 >100). Similar to SARS-CoV-2-specific IgG, the neutralization titers increased sharply one week after vaccination (median fold increase 10.8 (IQR 4.1-26.0)). A further increase was observed one month after the first dose (additional median fold increase 0.8 (IQR 0.1-2.4), achieving higher titers than observed in the control group ( Figure 2B , S2C-D, Table S4 ). However, further increases after the second dose were minimal (median fold J o u r n a l P r e -p r o o f increase between weeks 4 and 8 = 0.4 (IQR -0.1-1.1)). Using the Bayesian ANOVA model, we estimated that the relative increase in mean neutralizing responses were non-trivial on weeks 1 (95% CrI: 0.66, 0.81) and 4 (95% CrI: 0.3, 0.23) but trivial on week 8 (95% Cri: -0.01, 0.13). Neutralization of VOCs was evaluated in a random selection of 30 participants with detectable WT D614G neutralization titers. While 11 of these 30 participants had undetectable neutralizing activity against one or more VOCs before vaccination, neutralization titers rose sharply after the 1st vaccine dose and were measurable at that time in all participants to all four VOCs. Further increases in neutralization titers were observed at 8 weeks postvaccination (4 weeks post-2 nd dose) to the Alpha and Delta variant, similar to the increase of WT D614G neutralization between week 1 and week 8 ( Figure 2C , S2E; Table S4 ). The differences between WT D614G and Alpha and Delta VOC neutralization titers were therefore trivial, but not for Beta (95% CrI: -0.24, -0.07) and Gamma (95% CrI: -0.41, -0.11) of which neutralization titers lagged behind at week 8 post-vaccination ( Figure S2E ; Table S4 ). We repeated our analysis including the second phase decay rate of post-infection neutralizing response as an additional variable to neutralization titers measured 4 weeks after vaccination ( Figure S3B ). In this reanalysis, using a smaller subset of participants (n=66) for whom we were able to estimate their post-infection antibody decay rate, age (95% CrI: -0.09, 0.19), week 0 neutralization titers (95% CrI: -0.01, 0.47) and post-infection decay rate (95% CrI: -0.12, 0.26) were found to have trivial effects. However, sex (95% CrI: -0.37, -0.01), time since symptom onset (95% CrI: 0.05, 0.48) and week 1 neutralization titers (95% CrI: 0.06, 0.49) continue to have non-trivial effects. We further analyzed the differentiation in neutralization levels between participants grouped by age, sex and time since symptom onset using the Bayesian ANOVA model. Before vaccination, neutralization levels could not be meaningfully distinguished between different groups of the aforementioned variables as their estimated posterior distributions of mean neutralization titers overlapped with each other ( Figure S4A ). After vaccination, mean neutralization levels were discernible between different sexes (95% CrI difference, week 1 (0.02, 0.24), week 4: (-0.27, -0.01)). However, post-vaccination neutralizing responses remained indiscernible between different age groups ( Figure S4B -C). This indicates that while neutralization levels overlapped widely between different age groups, younger individuals were expected to achieve higher neutralizing response one week after vaccination and older individuals were expected to have a larger increase in neutralization titers between week one and four. As for the length of time since symptom onset, individuals with illness onset dating more than 1 year before vaccination yielded discernibly higher mean neutralizing titers ( Figure 3C and S4B-C). While most of the recruited participants with severe or critical COVID-19 disease (n=19/33; 58%) were diagnosed with Covid-19 more than a year before vaccination and these individuals were expected to have higher neutralizing response post-infection, almost half of the participants with times since symptom onset >12 months (n=16/35; 48%) had mild to moderate COVID-19 disease severity. Furthermore, the higher post-vaccination neutralizing response among participants with >12 months since illness onset was still observed when only those with mild or moderate COVID-19 disease were included in the analysis ( Figure S4D ). Pre-vaccination neutralization titers from these individuals were also not discernibly different to those with shorter times since symptom onset ( Figure 3C The Bayesian multilevel regression model showed that pre-vaccination neutralization titers as well as time since infection were associated with higher neutralization titers after vaccination. This may suggest that pre-existing antibodies potentially augment immune responses, perhaps through the formation of immune complexes by antibodies binding the vaccine antigen 16, 17 , and that over time the memory B cells accumulate higher affinity resulting in higher recall response after vaccination 2 . In keeping with other studies 9,18-21 , we observed age and male sex inversely correlated with vaccine responses early after vaccination, however this levelled out again four weeks after vaccination, even though variation in the neutralization titers was large and effect sizes overlapped between the sex and age groups. 28 . Nevertheless, a degree of cross-neutralization of these four VOCs was observed in all participants already after a single dose in previously infected individuals, also against the highly prevalent Delta variant with titers favourably compared to Beta and Gamma. Longer follow up will determine the longevity of the immune response and protective efficacy after single and double dosing in previously infected individuals. In addition, while similar antibody boost responses would be anticipated for other SARS-CoV-2 vaccines, this needs to be confirmed in future studies, especially for non-mRNA vaccines. In the meantime, the findings of this study support wide implementation of a single-dose mRNA vaccine strategy after prior SARS-CoV-2 infection to save vaccines and resources, hence expediting vaccination uptake at community levels worldwide. There are several limitations of our study. As only symptomatic COVID-19 patients were enrolled in the RECoVERED cohort we were unable to study vaccine responses after previous asymptomatic SARS-CoV-2 infection. However, an earlier study in HCW has observed no differences in antibody responses to a mRNA vaccine between individuals with prior asymptomatic and symptomatic SARS-CoV-2 infections 13 . Furthermore, the SARS-CoV-2 naive HCW controls were not matched with the previously infected cohort participants for potentially relevant factors such as age, sex or the presence of comorbidities. However, given that antibody responses in the healthier and younger HCW controls were lower, combined with our finding that age is inversely correlated with early antibody vaccine response, the observed difference in vaccine response might even have been more pronounced if controls were matched. Only serological responses have been studied as these have been shown to strongly correlate with vaccine efficacy 29, 30 . However, other immune components such as T cells likely play important roles in illness protection as well. Finally, participants with severe COVID-19 were overrepresented in the subgroup with >12 months interval between infection and vaccination, but fold increases in neutralization were very similar for all time interval subgroups, independent of disease severity. (Table S2) . Median with interquartile range is depicted. Area of binding values below detection limit are shaded in grey. (Table S4 ). Area of neutralization titers below detection limit are shaded in grey. (Table S4 ). Area of neutralization titers below detection limit are shaded in grey. Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Menno de Jong (m.d.dejong@amsterdamumc.nl). This study did not generate new unique reagents. Any additional information required to reanalyse the data reported in this paper is available from the lead contact upon request. The Pseudovirus neutralization assay was performed as previously described ( The luciferase activity in cell lysates was measured using the Nano-Glo Luciferase Assay System (Promega) and GloMax system (Turner BioSystems). The 50% inhibitory dilution (ID50) titers were determined as the serum dilution at which infectivity was inhibited by 50% using a non-linear regression curve fit (GraphPad Prism software version 8.3). We estimated the decay rates in antibody response after infection using data based on 66 participants for which serum samples were collected for at least two timepoints 4 weeks after their respective symptom onset date. We performed Bayesian hierarchical linear regression of the mean log response variable (〈 〉) against time since symptom onset ( ), partially pooling decay rates across participants . Following previous analyses by others 36 , two models were considered, including a single-phase constant decay model: and a two-phase decay model: and ,1 are the participant-specific intercept and constant decay rate. In the two-phase decay model, ,2 is the difference in decay rates between the first and second phase. 0 is the estimated transition timepoint between the two phases. Detailed prior formulations of , and 0 are described in the Supplementary Materials. The Watanabe-Akaike information criterion was computed to assess model fit. A Bayesian hierarchical generalization of the one-way ANOVA model was used to compare control, pre-and post-vaccination neutralizing and IgG antibody binding titers. Differences between groups are reported as differences in effect sizes. A difference in effect size is non-trivial if it is non-zero, and substantial if greater/lower than where . is the normalized effects of variable for participant and is the participant-specific intercept. We assumed that the observed mean-centered and scaled neutralization values follow a Student-T distribution about the predicted 〈 〉 with error-term standard deviation with degrees of freedom: We assumed that is exponentially distributed with a mean of 30 such that high prior probability was allocated over parameter values that describe the range from normal to heavytailed data under the Student-T distribution 37 : The intercepts were assumed to be normally distributed about a common mean intercept 〈 〉 with standard deviation : The participant-specific effect sizes . of variable were assumed to be normally distributed about a common mean effect size 〈 〉 with a predictor-specific standard deviation : . ~ (〈 〉, ) Weakly informative priors were placed on all standard deviation terms to constrain parameter inferences within biologically and mathematically plausible values 38 : A weakly informative Gaussian prior was also placed for the mean intercept 〈 〉 while a weakly informative Student-T prior was placed on the mean effect size 〈 〉 for each predictor : Week 1 <6m 6-12m 12m Herd Immunity and Implications for SARS-CoV-2 Control Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection Robust neutralizing antibodies to SARS-CoV-2 infection persist for months SARS-CoV-2 Antibody Response in Persons with Past Natural Infection COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2 mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2 COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine A Crucial Role for Infected-Cell/Antibody Immune Complexes in the Enhancement of Endogenous Antiviral Immunity by Short Passive Immunotherapy Immunoregulatory functions of immune complexes in vaccine and therapy Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination Factors That Influence the Immune Response to Vaccination Sex differences in immune responses Sex differences in vaccine-induced humoral immunity Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination SARS-CoV-2 Lambda Variant Remains Susceptible to Neutralization by mRNA Vaccine-elicited Antibodies and Convalescent Serum Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 Evidence for antibody as a protective correlate for COVID-19 vaccines Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection Evolution of COVID-19 symptoms during the first 9 months after illness onset Serologic Surveillance and Phylogenetic Analysis of SARS-CoV-2 Infection in Hospital Health Care Workers Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses Evolution of immune responses to SARS-CoV-2 in mildmoderate COVID-19 Doing Bayesian data analysis : a tutorial with R and BUGS Recombinant DNA pHIV-1NL43ΔENV-NanoLuc plasmid Obtained from the lab of Paul Bieniasz N/A SARS-CoV-2-SΔ19 plasmid The authors wish to thank all RECoVERED and S3 study participants; Mathieu A.